55 results about "Bronchial dilation" patented technology

The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to beta2-adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

This invention further relates to a method for preventing or treating diseases or conditions of the oral cavity, throat or nose of warm-blooded animals including humans. More particularly, the invention pertains to a composition and method for spraying essential oils to the oral cavity, throat or nasal mucosa as cyclodextrin inclusion complexes. The spray composition includes a cyclodextrin in an amount of from about 0.1% w / v to about 20% w / v; at least one essential oil in an amount of from about 0.001% w / v to about 5.0% w / v; an effective amount of an antimicrobial preservative composition; and water. The composition may further comprise an alcohol co-solvent, a thickening agent, a sweetener, an antitussive, an anticholinergic, a decongestant, an antihistamine, an astringent, an anti-inflammatory steroid composition, a vitamin, a respiratory stimulant, a mucolytic agent, a bronchodilator, a beta-antagonist, an antidiarrheal agent, or combinations thereof.

Crystalline spherical inhalation particles incorporating a combination of two or more different active ingredients and a process for the preparation thereof. The particles have a narrow particle size distribution, rough surfaces and improved stability. The inhalation particles of the invention are particularly useful in the administration of a combination medicament, e.g. a combination of an anti-inflammatory agent and a bronchodilator, by inhalation in the treatment of asthma and other respiratory disorders.

The present disclosure provides methods for improving drug efficacy in a patient having an obstructed airway in a lung. Such methods modulate nerve activity in the autonomic nervous system of a patient to reduce obstruction of an airway in a lung of the patient prior to administering a drug to the patient. These methods are especially useful in improving efficacies of bronchodilators in treating obstructive lung diseases, such as chronic obstructive pulmonary disease.

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

Analogs of the prostaglandin PGE1 are disclosed. These compounds exhibit uterotonic properties, enhancing the response to PGF2 alpha in isolated rat uteri. The compounds also exhibit other pharmacological properties, as inhibitors of gastric acid secretion, hypotensives, and bronchodilators. Processes for making the analogs, useful intermediates, and pharmaceutical preparations are also presented.

A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.

A prodrug utilizes an enzyme whose enzymatic activity is different in between the target site of the drug and the site to express side effects, the prodrug having a substituent cleavable with the enzyme and being activated by cleaving the substituent with the enzyme. As the target site of the drug, for example, a respiratory organ can be mentioned and as the site to express side effects, for example, the heart can be mentioned. As the example of the drug, a bronchodilator can be mentioned and as the example of the enzyme, a glycosidase (for example, β-glucuronidase) can be mentioned. Furthermore, the substituent is, for example, a glycosyl group composed of a monosaccharide or an oligosaccharide. Use of the enzyme enables reducing the side effects of a drug of the type whose target site is different from the site to express side effects.

The present invention is directed to methods and compositions for treating pulmonary disease comprising delivering directly to a patient's lungs a therapeutically effective amount of oxybutynin in combination with one or more pharmaceutically effective agents. Oxybutynin may be selected from the group consisting of, but not limited to, a xinafoate salt, a palmitate salt, a pamoic salt, a resonate salt, a laurate salt and other salts. The pharmaceutically effective agents comprise bronchodilators, antiinflammatories, corticosteroids, corticosteroid reversal agent or alveolar growth agents or other agents selected from proteinase or protease inhibitors.

The present invention relates to the use of a bronchodilator in combination with one or more further active ingredients for the treatment of respiratory disorders and especially asthma and chronic obstructive pulmonary disease (COPD), and to pharmaceutical compositions containing said active ingredients. In particular, the invention relates to the use of the long-acting β2-agonist 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1methylethyl]amino]ethyl-2(1H)quinolinone and / or physiologically acceptable salts and / or solvates thereof as a bronchodilator in combination with other active ingredients.

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

Novel pyrazolopyridylpyridazinone derivatives characterized by being represented by general formula (1) and pharnacologically acceptable salts thereof, which exhibit a phosphodiesterase inhibiting activity and have a selective potent bronchodilating effect on the respiratory tract; a process for the preparation of them; and bronchodilators containing the same as the active ingredient; wherein R1 is C1-C4 lower alkyl or C3-C6 cycloalkyl; and R2, R3, R4 and R5 are each independently hydrogen, C1-C4 lower alkyl or phenyl, or alternatively R3 and R5 may be united to form a double bond.

The invention discloses a pharmaceutical composition for the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma, which is composed of a glucocorticoid, a bronchodilator and a pharmaceutically acceptable auxiliary material or carrier; the composition is a preparation for oral use. The glucocorticoid in the inventive pharmaceutical composition is selected from prednisone, prednisolone, methylprednisolone, betamethasone, decamethasone or hydrocortisone; the bronchodilator is selected from formoterol, clenbuterol, procaterol or theophylline. The inventive composition has better therapeutic effect on the COPD and the bronchial asthma than independent administration of two ingredients, and has synergistic effect. The composition has easily-available raw materials, inexpensive price and increased medicine taking compliance as well as plays a significant role in preventing and treating the COPD and the bronchial asthma of patients in vast rural areas and patients in low-income class of the city in China.

The present invention is related to the treatment and prevention of pulmonary vascular diseases. Administration of dehydroepiandrosterone (DHEA) has been found to prevent and decrease pulmonary artery hypertension. Accordingly, the invention discloses methods of treating or preventing pulmonary vascular diseases such as pulmonary artery hypertension by pulmonary administration of compositions containing DHEA, DHEAS, DHEA analogs, or DHEA derivatives. Additionally, the DHEA, DHEAS, DHEA analogs, or DHEA derivatives may be used in combination with other pharmaceutical agents, such as bronchodilators, vasodilators, anti-inflammatory agents, and anti-infectious agents to treat pulmonary diseases.

An inhaler device to treat obstructive lung disease has an immediate acting bronchodilator medication, a dispenser housing for dispensing the immediate acting bronchodilator medication, and indicia on the dispenser housing to convey to a user that the inhaler device contains inhaler medication for for acute relief of obstructive lung disease symptoms.

The invention discloses a novel inhalant containing glucocorticoid and bronchodilator, that is, inhalable particles containing glucocorticoid and other medicine, wherein, the other medicine is selected from one of the following medicines: beta 2 receptor stimulant, anticholinergic agent, theophylline agent, leukotriene receptor antagonist, mast cell stabilizer and antihistamine.

A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid.

The compound of formula (I)is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.

The invention discloses a medicine composition mainly containing oral glucocorticoid and an oral bronchodilator, as well as application thereof in preparing medicines for treating chronic obstructive pulmonary diseases (COPD) and bronchial asthma, which belongs to the technical field of medicine preparations. The oral glucocorticoid contained in the medicine composition is prednisone, prednisolone or methylprednisolone, and the oral bronchodilator is formoterol, clenbuterol or euphylline. The curative effect of the composition for treating the COPD or the bronchial asthma is better than that of separately using the two composition ingredients one after another, and the composition has the characteristics of synergistic action and low cost. Thus, the combination preparation of the oral glucocorticoid and the oral bronchodilator is of great significance to the treatment and the prevention of the COPD and the bronchial asthma of patients of lower income groups in wide rural and urban areas in China.

pharmaceutical combination or composition for inhalation a fixed combination (A) L-lysine N-acetylcysteinate and (B) a bronchodilator agent for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory or obstructive respiratory disease.

The invention relates to a method for adopting a diaphragmatic electromyogram to judge an airway resistance, namely applying the change of the ratio of the diaphragmatic electromyogram to an airflow to judge change of a lower airway resistance. The diaphragmatic electromyogram can be recorded through an esophagus electrode and can be also recorded through a surface electrode. An airflow signal can be obtained through various flow meters and is represented in the form of peak flow rate, mean flow rate, tidal volume and the like. The change of the lower airway resistance is reflected through the change of the ratio of the diaphragmatic electromyogram to the airflow. When a bronchial provocation test is performed, airway shrinkage of an asthma patient causes increase of the lower airway resistance, and the ratio of the diaphragmatic electromyogram to the airflow rises at the moment. Similar to the principle, a bronchodilator causes airway relaxation during asthmatic attack, accordingly the airway resistance is reduced, and the ratio of the diaphragmatic electromyogram to the airflow is also reduced with the resistance reduction. The method does not need a lung function instrument, and medical resources are saved. A patient only needs to perform eupnea, and a complicated checking routine is simplified. The method is suitable for checking of airway hyperresponsiveness and airway obstruction reversibility of lots of patients, especially the old, children and unconscious patients.

Optically active 1-substituted phenyl-2-nitro alcohol derivatives having the formula (1) and the process for producing thereof, and 1-substituted phenyl-2-amino alcohol derivatives having the formula (2) and the process for producing thereof from the optically active 1-substituted phenyl-2-nitro alcohol derivatives. From these nitro alcohols, pharmaceuticals such as (R)-albutamin and (R)-sarmeterol useful as a bronchodilator is obtained via optically active amino alcohols which are useful pharmaceutical intermediates.

The compound of formula (I)is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.